Why a new pet medication may have a small but significant impact on health

People with allergies to sheep and dogs may be taking the first steps toward a healthier future.

A new pet drug from a veterinary medical device maker may have less of a direct impact on allergy sufferers, but it does raise the possibility that the drugs could also have health benefits for pets, researchers say.

The pet drug, known as dewormantel, has been in development for several years.

It is designed to be used to treat allergies to goats, sheep, cattle, horses, chickens and ducks.

It has been used in animals for several decades, including for dogs.

The new drug is designed by researchers at Pfizer Inc. and is part of Pfizer’s effort to create a new class of allergy drugs.

Pfizer is using a technique called protein-protein interaction to help make the drugs more effective in animals.

The drug has been approved by the Food and Drug Administration in the U.S. for the treatment of severe allergic reactions.

Pfizers research shows that the drug can help relieve symptoms for people with severe allergies to those animals.

Pfists research also shows that it can be effective in people with milder allergies to certain types of animals.

One study, published online in the journal Allergy, showed that people with a milder allergy to horses were able to tolerate deworming with the drug.

The research also showed that a dose of deworment that was just a quarter the recommended daily dose, which is about the amount a dog takes for two weeks, could be effective for people suffering from allergies to pigs and chickens.

That’s good news for people who don’t want to use dewormers or have allergies to any of the animals that are treated.

It could be a breakthrough for people in the United States, where there are fewer pets.

It may also help people in Europe and Asia.

The U.K. and Germany are the only countries that have used dewormors.

But the drug is also not approved for use in humans.

Pfisers research showed that mice that received the drug had reduced levels of antibodies to the protein-protein interaction, which makes the drug more effective.

People with severe allergic disorders have allergies that affect their bodies in a way that can make them more vulnerable to infections.

Dewormers have a similar mechanism of action to how humans get infections, and they may be a more effective way to control infections.

People suffering from severe allergic conditions are also more likely to use the drugs, and it could make the drug less of an issue for them.

That means it’s likely that people who take the drug would be less likely to be infected by a pet, said David Hwang, an allergist at the University of Michigan.

The study showed that, in mice, the drug helped prevent mice from developing a rare disease that can affect a large percentage of humans: Mycobacterium tuberculosis.

The researchers say that while the drug works in mice that live in a very harsh environment, it could be helpful for people living in areas with less environmental pressure.

People who have asthma are especially vulnerable to the disease.

There are several types of tuberculosis in the human body, including B-Tox, a type that can cause severe lung damage.

The Pfizer drug might be able to treat the disease if it’s effective in humans, Hwang said.

The findings have been published in the Journal of Allergy and Clinical Immunology.

The results were based on mice that were treated with dewormants at doses that were similar to those prescribed to humans.

A drug called Lassa, which was developed by Pfizer, has a similar effect in people.

The Lassas drug, called dewormir, was tested in mice.

The company said it was working with researchers in Japan and China to develop an antibody that could be used in people who are not allergic to sheep or dogs.